期刊文献+

CO_2激光联合他克莫司治疗白癜风临床观察 被引量:2

CO_2 Laser Combined with Tacrolimus for Vitiligo:Clinical Observation
下载PDF
导出
摘要 目的观察CO2激光联合他克莫司治疗白癜风临床观察的疗效。方法选取符合要求的白癜风患者30例。治疗组先予CO2激光烧灼皮损及距皮损边缘0.3cm正常皮肤,待结痂后即予外涂他克莫司。对照组自身对照,单用他克莫司外涂,两组同时连用他克莫司两个月,停用一个月后观察疗效。结果治疗组显效率为73.33%,对照组显效率为43.33%。结论 CO2激光联合他克莫司治疗白癜风疗效好,不良反应少。 Objective To observe the efficacy of tacrolimus combined with CO2 laser for vitiligo. Methods Thirty cases of vitiligo were enrolled in the study. In the treatment group,the lesions were burned to 0.3cm from the edge of normal skin by using CO2 laser,and then treated by tacrolimus after the scars were formed. In the self-controlled group, only tacrolimus was used for the lesions. Both groups received tacrolimus for 2 months and clinical efficacy was evaluated one month after the tacrolimus treatment. Results The markedly effective rate of the treatment group was 73.33%,and it was 43.33% in the control group. Conclusion Tacrolimus combined with CO2 laser is effective in the treatment of vitiligo, with fewer adverse reactions.
出处 《中国现代医生》 2010年第11期35-36,共2页 China Modern Doctor
基金 中山市卫生局科研立项项目(编号:2009099)
关键词 白癜风 他克莫司 CO2激光 Vitiligo CO2 laser Tacrolimus
  • 相关文献

参考文献8

二级参考文献48

  • 1汪科,朱学骏.局部免疫调节剂他克莫司、吡美莫司在皮肤病的应用[J].药物不良反应杂志,2005,7(5):345-348. 被引量:19
  • 2常建民.他克莫司治疗白癜风的现状和机制[J].临床皮肤科杂志,2007,36(2):123-124. 被引量:9
  • 3刁庆春,薛梅,桑小川,陈谊,谭励,阎国富.308nm准分子激光治疗白癜风临床疗效观察[J].临床皮肤科杂志,2007,36(6):398-399. 被引量:23
  • 4Naughton GK, Reggiardo D, Bystryn JC. Correlation between vitiligo antibodies and extent of depigmentation in vitiligo. J Am Acad Dermatol, 1986, 15(5 Pt 1 ): 978-981.
  • 5Steitz J,Wenzel J, Gaffal E, et al. Initiation and regulation of CD8^+ T cells recognizing melanocytic antigens in the epidermis: implications for the pathophysiology of vitiligo. Eur J Cell Biol, 2004, 83(11-12): 797-803.
  • 6Hirobe T. Role of keratinocyte-derived factors involved in regulating the proliferation and differentiation of mammalian epidermal melanocytes. Pigment Cell Res, 2005, 18( 1 ): 2-12.
  • 7Oliveira SH, Lukacs NW. Stem cell factor: a hemopoietic cytokine with important targets in asthma. Curr Drug Targets Inflamm Allergy, 2003, 2(4): 313-318.
  • 8Kunisada T, Yamazaki H, Hayashi SI. Review: ligands for receptor tyrosine kinases expressed in the skin as environmental factors for melanocyte development.J Investig Dermatol Symp Proc, 2001, 6( 1 ): 6-9.
  • 9Okura M, Maeda H, Nishikawa S, et al. Effects of monoclonal anti-c-kit antibody (ACK2) on melanocytes in newborn mice. J Invest Dermatol, 1995, 105(3): 322-328.
  • 10Lan CC, Chen GS, Chiou MH, et al. FK506 promotes melanocyte and melanoblast growth and creates a favourable milieu for cell migration via keratinocytes: possible mechanisms of how tacrolimus ointment induces repigmentation in patients with vitiligo. Br J Dermatol, 2005, 153(3): 498-505.

共引文献821

同被引文献21

  • 1白癜风临床分型及疗效标准(2003年修订稿)[J].中华皮肤科杂志,2004,37(7):440-440. 被引量:801
  • 2Halder RM, Chappell JL. Vitiligo update [ J ]. Semin Cutan Med Surg, 2009, 28(2) : 86 -92.
  • 3Cducci R, Lotti T, Moretti S. Vitiligo: an update on current pharmacotherapy and future directions [ J ]. Expert Opin Pharmacother, 2012, 13(13) : 1885 -1899.
  • 4Hossani-Madani AR, Halder RM. Topical treatment and combination approaches for vitiligo: new insights, new developments[ J]. G Ital Dermatol Venereol, 2010, 145 ( 1 ) : 57 - 78.
  • 5Kotobuki Y, Tanemura A, Yang L, et al. Dysregulation of melanocyte function by Th17-related cytokines: significance of Th17 cell infiltration in autoimmune vitiligo vulgaris[ J ]. Pigment Cell Melanoma Res, 2012, 25(2) : 219 -230.
  • 6Wang CQ, Cruz-Inigo AE, Fuentes-Duculan J, et al. Th17 cells and activated dendritic cells are increased in vitiligo lesions [ J/OA ]. PLoS One, 2011, 6(4) : e18907.
  • 7Zhu S, Qian Y. IL-17/IL-17 receptor system in autoimnmne disease: mechanisms and therapeutic potential[ J]. Clin Sci (Lond), 2012, 122(11) : 487 -511.
  • 8Sun J, Hou J, Li D, et al. Enhancement of HIV-1 DNA vaccine immunogenicity by BCG-PSN, a novel adjuvant [ J]. Vaccine, 2013, 31(3) : 472 -479.
  • 9Luo Y, Jiang W, Da Z, et al. Subunit vaccine candidate AMM down-regulated the regulatory T cells and enhanced the protective immunity of BCG on a suitable schedule [ J ]. Scand J Immunol, 2012, 75(3) : 293 -300.
  • 10Malhotra N, Dytoc M. The pathogenesis of vitiligo[J]. J Cutan Med Surg, 2013, 17(3): 153-172.

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部